Forte Biosciences FBRX

$ 14.75 8.86%

Quarterly report 2024-Q3
added 11-14-2024

Forte Biosciences Balance Sheet 2011-2024 | FBRX

Annual Balance Sheet Forte Biosciences

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-	-58.8 M	-2.19 M	-14.6 M	-25.1 M	15.5 M	9.5 M	-	-	-	-
Long Term Debt	-	-	-	-	-	26.2 M	3.62 M	13.8 M	17 M	-	-	-	-
Long Term Debt Current	-	-	-	-	416 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	10.5 M	28.4 M	3.66 M	14 M	17.2 M	-	-	-	-
Total Current Liabilities	3.67 M	3.18 M	1.76 M	2.26 M	13.2 M	16.5 M	17.3 M	-	-	-	-	-	-
Total Liabilities	-	-	-	2.26 M	12.4 M	44.9 M	21 M	28.4 M	23.1 M	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-119 M	-87 M	-73.2 M	-51.5 M	-4.97 M	-216 M	-167 M	-128 M	-94.5 M	-	-	-	-
Total Assets	39 M	42 M	43.3 M	61.2 M	7.66 M	103 M	92.1 M	35.4 M	62.2 M	-	-	-	-
Cash and Cash Equivalents	37.1 M	41.1 M	42 M	58.8 M	8.99 M	40.8 M	35.9 M	5.51 M	8.15 M	-	-	-	-
Book Value	39 M	42 M	43.3 M	59 M	-4.77 M	58.1 M	71.1 M	7 M	39.1 M	-	-	-	-
Total Shareholders Equity	35.3 M	38.8 M	41.5 M	59 M	-4.77 M	58.1 M	71.1 M	-124 M	-92.3 M	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Forte Biosciences

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.91 M	4.03 M	9.12 M	22.1 M	24.1 M	26.2 M	26.2 M	26.2 M	26.2 M	3.62 M	3.62 M	3.62 M	3.62 M	10.2 M	10.2 M	10.2 M	10.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16.6 M	17.3 M	50.9 M	48.7 M	49.9 M	44.9 M	44.9 M	44.9 M	44.9 M	21 M	21 M	21 M	21 M	28.4 M	28.4 M	28.4 M	28.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9 K	18 K	27 K	36 K	36 K	36 K	36 K	36 K	36 K	36 K	36 K	45 K	45 K	45 K	45 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-147 M	-138 M	-126 M	-119 M	-113 M	-103 M	-93.8 M	-87 M	-82.2 M	-78.8 M	-75.7 M	-73.2 M	-69.8 M	-62.1 M	-56.3 M	-51.5 M	-51.5 M	-51.5 M	-51.5 M	-4.97 M	-4.97 M	-4.97 M	-279 M	-216 M	-216 M	-216 M	-216 M	-167 M	-167 M	-167 M	-167 M	-128 M	-128 M	-128 M	-128 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	17.9 M	26.1 M	32 M	39 M	47.9 M	31.2 M	36.7 M	42 M	45.1 M	39.7 M	41.3 M	43.3 M	47.4 M	52.9 M	57.1 M	61.2 M	61.2 M	61.2 M	61.2 M	7.66 M	7.66 M	7.66 M	28.2 M	103 M	103 M	103 M	103 M	92.1 M	92.1 M	92.1 M	92.1 M	35.4 M	35.4 M	35.4 M	35.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	16.4 M	24.5 M	30.4 M	37.1 M	46.2 M	20.4 M	35.9 M	41.1 M	44 M	38.5 M	40 M	42 M	45.7 M	50.8 M	54.8 M	58.8 M	58.8 M	58.8 M	58.8 M	6.94 M	6.94 M	6.94 M	8.99 M	40.8 M	40.8 M	40.8 M	40.8 M	35.9 M	35.9 M	35.9 M	35.9 M	5.51 M	5.51 M	5.51 M	5.51 M	8.15 M	-	-	-	4.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	-	-	-	-	42 M	45.1 M	39.7 M	41.3 M	43.3 M	47.4 M	52.9 M	57.1 M	61.2 M	61.2 M	61.2 M	44.7 M	-9.65 M	-43.3 M	-41.1 M	-21.7 M	58.1 M	58.1 M	58.1 M	58.1 M	71.1 M	71.1 M	71.1 M	71.1 M	7 M	7 M	7 M	7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	9.37 M	17 M	28.7 M	35.3 M	40.4 M	24.9 M	32.9 M	38.8 M	42.8 M	38.2 M	40 M	41.5 M	43.6 M	49.9 M	54.7 M	59 M	59 M	59 M	59 M	-4.77 M	-4.77 M	-4.77 M	10.8 M	-736 K	58.1 M	58.1 M	58.1 M	71.1 M	71.1 M	71.1 M	71.1 M	-124 M	-124 M	-124 M	-124 M	-92.3 M	-	-	-	-70.4 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency